Cancer Communications
indexed by SCI
BMC

Review
Pathological transition as the arising mechanism for drug resistance in lung cancer
Yueqing Chen, Waiying Yvonne Tang, Xinyuan Tong & Hongbin Ji
State Key Laboratory of Cell Biology, CAS Center for Excellence on Molecular Cell Science, Innovation Center for Cell Signaling Network, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, 200031, P. R. China
[Abstract] Despite the tremendous efforts for improving therapeutics of lung cancer patients, its prognosis remains disappointing. This can be largely attributed to the lack of comprehensive understanding of drug resistance leading to insufficient development of effective therapeutics in clinic. Based on the current progresses of lung cancer research, we classify drug resistance mechanisms into three different levels: molecular, cellular and pathological level. All these three levels have significantly contributed to the acquisition and evolution of drug resistance in clinic. Our understanding on drug resistance mechanisms has begun to change the way of clinical practice and improve patient prognosis. In this review, we focus on discussing the pathological changes linking to drug resistance as this has been largely overlooked in the past decades.
Cancer Communications   Epub date: 10/1/2019   doi:10.1186/s40880-019-0402-8
[PDF Full-text]

[ Html full-text] (BioMed Central)

[ PubMed]

Cite this article

Yueqing Chen, Waiying Yvonne Tang, Xinyuan Tong & Hongbin Ji. Pathological transition as the arising mechanism for drug resistance in lung cancer. Cancer Commun (Lond). 2019, 39:53. doi:10.1186/s40880-019-0402-8


Export citations

EndNote

CJC Wechat 微信公众号


 

Editorial Manager


CC adopts ScholarOne Manuscripts to manage its submissions from Nov.1, 2019

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by BioMed Central

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China